AustralieFrV1, Main, Exploration, bibRecord, 004184

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Identifieur interne : 004184 ( Main/Exploration ); précédent : 004183; suivant : 004185

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Auteurs : T. M. Beer [États-Unis] ; A. J. Armstrong [États-Unis] ; D. E. Rathkopf [États-Unis] ; Y. Loriot [France] ; C. N. Sternberg [Italie] ; C. S. Higano [États-Unis] ; P. Iversen [Pays-Bas] ; S. Bhattacharya [États-Unis] ; J. Carles [Espagne] ; S. Chowdhury [Royaume-Uni] ; I. D. Davis [Australie] ; J. S. De Bono [Royaume-Uni] ; C. P. Evans [États-Unis] ; K. Fizazi [France] ; A. M. Joshua [Canada] ; C.-S. Kim [Corée du Sud] ; G. Kimura [Japon] ; P. Mainwaring [Australie] ; H. Mansbach [États-Unis] ; K. Miller [Allemagne] ; S. B. Noonberg [États-Unis] ; F. Perabo [États-Unis] ; D. Phung [États-Unis] ; F. Saad [Canada] ; H. I. Scher [États-Unis] ; M.-E. Taplin [États-Unis] ; P. M. Venner [Canada] ; B. Tombal [Belgique]

Source :

The New England journal of medicine [ 0028-4793 ] ; 2014.

RBID : Pascal:14-0207191

Descripteurs français

Pascal (Inist)
- Cancer de la prostate, Chimiothérapie, Métastase, Métastatique, Médecine.
Wicri :
- topic : Médecine.

English descriptors

KwdEn :
- Chemotherapy, Medicine, Metastasis, Metastatic, Prostate cancer.

Abstract

BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy. METHODS In this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalutamide (at a dose of 160 mg) or placebo once daily. The coprimary end points were radiographic progression-free survival and overall survival. RESULTS The study was stopped after a planned interim analysis, conducted when 540 deaths had been reported, showed a benefit of the active treatment. The rate of radiographic progression-free survival at 12 months was 65% among patients treated with enzalutamide, as compared with 14% among patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% confidence interval [CI], 0.15 to 0.23; P<0.001). A total of 626 patients (72%) in the enzalutamide group, as compared with 532 patients (63%) in the placebo group, were alive at the data-cutoff date (29% reduction in the risk of death; hazard ratio, 0.71; 95% CI, 0.60 to 0.84; P<0.001). The benefit of enzalutamide was shown with respect to all secondary end points, including the time until the initiation of cytotoxic chemotherapy (hazard ratio, 0.35), the time until the first skeletal-related event (hazard ratio, 0.72), a complete or partial soft-tissue response (59% vs. 5%), the time until prostate-specific antigen (PSA) progression (hazard ratio, 0.17), and a rate of decline of at least 50% in PSA (78% vs. 3%) (P<0.001 for all comparisons). Fatigue and hypertension were the most common clinically relevant adverse events associated with enzalutamide treatment. CONCLUSIONS Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer.

Affiliations:

Allemagne, Australie, Belgique, Canada, Corée du Sud, Espagne, France, Italie, Japon, Pays-Bas, Royaume-Uni, États-Unis
Angleterre, Berlin, Californie, Catalogne, Grand Londres, Hovedstaden, Latium, Massachusetts, Oregon, Québec, Région capitale de Séoul, Région de Bruxelles-Capitale, Région de Kantō, Washington (État), État de New York
Barcelone, Berlin, Boston, Bruxelles, Copenhague, Londres, Montréal, Portland, Rome, San Francisco, Seattle, Séoul, Tokyo
Université de Washington

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000289
to stream PascalFrancis, to step Curation: 005B73
to stream PascalFrancis, to step Checkpoint: 000329
to stream Main, to step Merge: 004253
to stream Main, to step Curation: 004184

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Enzalutamide in Metastatic Prostate Cancer before Chemotherapy</title>
<author><name sortKey="Beer, T M" sort="Beer, T M" uniqKey="Beer T" first="T. M." last="Beer">T. M. Beer</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>OHSU Knight Cancer Institute, Oregon Health and Science University</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Portland</settlement>
<region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Armstrong, A J" sort="Armstrong, A J" uniqKey="Armstrong A" first="A. J." last="Armstrong">A. J. Armstrong</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke Cancer Institute Divisions of Medical Oncology and Urology, Duke University</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Durham, NC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rathkopf, D E" sort="Rathkopf, D E" uniqKey="Rathkopf D" first="D. E." last="Rathkopf">D. E. Rathkopf</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>25 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Loriot, Y" sort="Loriot, Y" uniqKey="Loriot Y" first="Y." last="Loriot">Y. Loriot</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut Gustave Roussy, University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>University of Paris Sud</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sternberg, C N" sort="Sternberg, C N" uniqKey="Sternberg C" first="C. N." last="Sternberg">C. N. Sternberg</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>San Camillo and Forlanini Hospitals</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Higano, C S" sort="Higano, C S" uniqKey="Higano C" first="C. S." last="Higano">C. S. Higano</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Seattle Cancer Care Alliance, University of Washington</s1>
<s2>Seattle</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Seattle</settlement>
<region type="state">Washington (État)</region>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
<author><name sortKey="Iversen, P" sort="Iversen, P" uniqKey="Iversen P" first="P." last="Iversen">P. Iversen</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Rigshospitalet at the University of Copenhagen</s1>
<s2>Copenhagen</s2>
<s3>NLD</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhattacharya, S" sort="Bhattacharya, S" uniqKey="Bhattacharya S" first="S." last="Bhattacharya">S. Bhattacharya</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Medivation</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carles, J" sort="Carles, J" uniqKey="Carles J" first="J." last="Carles">J. Carles</name>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Medical Oncology, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chowdhury, S" sort="Chowdhury, S" uniqKey="Chowdhury S" first="S." last="Chowdhury">S. Chowdhury</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Guy's Hospital</s1>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Guy's Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Davis, I D" sort="Davis, I D" uniqKey="Davis I" first="I. D." last="Davis">I. D. Davis</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Monash University and Eastern Health</s1>
<s2>Clayton, VIC</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Monash University and Eastern Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Bono, J S" sort="De Bono, J S" uniqKey="De Bono J" first="J. S." last="De Bono">J. S. De Bono</name>
<affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Royal Marsden Hospital and Institute of Cancer Research</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Evans, C P" sort="Evans, C P" uniqKey="Evans C" first="C. P." last="Evans">C. P. Evans</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>University of California</s1>
<s2>Davis</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of California</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Comprehensive Cancer Center</s1>
<s2>Sacramento</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Comprehensive Cancer Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fizazi, K" sort="Fizazi, K" uniqKey="Fizazi K" first="K." last="Fizazi">K. Fizazi</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut Gustave Roussy, University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>University of Paris Sud</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Joshua, A M" sort="Joshua, A M" uniqKey="Joshua A" first="A. M." last="Joshua">A. M. Joshua</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Princess Margaret Cancer Centre</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Princess Margaret Cancer Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kim, C S" sort="Kim, C S" uniqKey="Kim C" first="C.-S." last="Kim">C.-S. Kim</name>
<affiliation wicri:level="3"><inist:fA14 i1="19"><s1>Asan Medical Center</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Corée du Sud</country>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kimura, G" sort="Kimura, G" uniqKey="Kimura G" first="G." last="Kimura">G. Kimura</name>
<affiliation wicri:level="3"><inist:fA14 i1="20"><s1>Nippon Medical School</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mainwaring, P" sort="Mainwaring, P" uniqKey="Mainwaring P" first="P." last="Mainwaring">P. Mainwaring</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Icon Cancer Care</s1>
<s2>South Brisbane</s2>
<s3>AUS</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Icon Cancer Care</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mansbach, H" sort="Mansbach, H" uniqKey="Mansbach H" first="H." last="Mansbach">H. Mansbach</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Medivation</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miller, K" sort="Miller, K" uniqKey="Miller K" first="K." last="Miller">K. Miller</name>
<affiliation wicri:level="3"><inist:fA14 i1="21"><s1>Charité-Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Noonberg, S B" sort="Noonberg, S B" uniqKey="Noonberg S" first="S. B." last="Noonberg">S. B. Noonberg</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Medivation</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perabo, F" sort="Perabo, F" uniqKey="Perabo F" first="F." last="Perabo">F. Perabo</name>
<affiliation wicri:level="1"><inist:fA14 i1="22"><s1>Astellas Pharma Global Development</s1>
<s2>Northbrook, IL</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Astellas Pharma Global Development</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Phung, D" sort="Phung, D" uniqKey="Phung D" first="D." last="Phung">D. Phung</name>
<affiliation wicri:level="1"><inist:fA14 i1="22"><s1>Astellas Pharma Global Development</s1>
<s2>Northbrook, IL</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Astellas Pharma Global Development</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Saad, F" sort="Saad, F" uniqKey="Saad F" first="F." last="Saad">F. Saad</name>
<affiliation wicri:level="3"><inist:fA14 i1="17"><s1>Centre Hospitalier de l'Université de Montréal</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>24 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Scher, H I" sort="Scher, H I" uniqKey="Scher H" first="H. I." last="Scher">H. I. Scher</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>25 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taplin, M E" sort="Taplin, M E" uniqKey="Taplin M" first="M.-E." last="Taplin">M.-E. Taplin</name>
<affiliation wicri:level="3"><inist:fA14 i1="23"><s1>Dana-Farber Cancer Institute</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>26 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Boston</settlement>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Venner, P M" sort="Venner, P M" uniqKey="Venner P" first="P. M." last="Venner">P. M. Venner</name>
<affiliation wicri:level="1"><inist:fA14 i1="18"><s1>Cross Cancer Institute and University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>27 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Cross Cancer Institute and University of Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tombal, B" sort="Tombal, B" uniqKey="Tombal B" first="B." last="Tombal">B. Tombal</name>
<affiliation wicri:level="3"><inist:fA14 i1="24"><s1>Cliniques Universitaires Saint-Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>28 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0207191</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0207191 INIST</idno>
<idno type="RBID">Pascal:14-0207191</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000289</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005B73</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000329</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000329</idno>
<idno type="wicri:doubleKey">0028-4793:2014:Beer T:enzalutamide:in:metastatic</idno>
<idno type="wicri:Area/Main/Merge">004253</idno>
<idno type="wicri:Area/Main/Curation">004184</idno>
<idno type="wicri:Area/Main/Exploration">004184</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Enzalutamide in Metastatic Prostate Cancer before Chemotherapy</title>
<author><name sortKey="Beer, T M" sort="Beer, T M" uniqKey="Beer T" first="T. M." last="Beer">T. M. Beer</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>OHSU Knight Cancer Institute, Oregon Health and Science University</s1>
<s2>Portland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Portland</settlement>
<region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Armstrong, A J" sort="Armstrong, A J" uniqKey="Armstrong A" first="A. J." last="Armstrong">A. J. Armstrong</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke Cancer Institute Divisions of Medical Oncology and Urology, Duke University</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Durham, NC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rathkopf, D E" sort="Rathkopf, D E" uniqKey="Rathkopf D" first="D. E." last="Rathkopf">D. E. Rathkopf</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>25 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Loriot, Y" sort="Loriot, Y" uniqKey="Loriot Y" first="Y." last="Loriot">Y. Loriot</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut Gustave Roussy, University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>University of Paris Sud</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sternberg, C N" sort="Sternberg, C N" uniqKey="Sternberg C" first="C. N." last="Sternberg">C. N. Sternberg</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>San Camillo and Forlanini Hospitals</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Higano, C S" sort="Higano, C S" uniqKey="Higano C" first="C. S." last="Higano">C. S. Higano</name>
<affiliation wicri:level="4"><inist:fA14 i1="06"><s1>Seattle Cancer Care Alliance, University of Washington</s1>
<s2>Seattle</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Seattle</settlement>
<region type="state">Washington (État)</region>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
<author><name sortKey="Iversen, P" sort="Iversen, P" uniqKey="Iversen P" first="P." last="Iversen">P. Iversen</name>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Rigshospitalet at the University of Copenhagen</s1>
<s2>Copenhagen</s2>
<s3>NLD</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhattacharya, S" sort="Bhattacharya, S" uniqKey="Bhattacharya S" first="S." last="Bhattacharya">S. Bhattacharya</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Medivation</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carles, J" sort="Carles, J" uniqKey="Carles J" first="J." last="Carles">J. Carles</name>
<affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Medical Oncology, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chowdhury, S" sort="Chowdhury, S" uniqKey="Chowdhury S" first="S." last="Chowdhury">S. Chowdhury</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Guy's Hospital</s1>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Guy's Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Davis, I D" sort="Davis, I D" uniqKey="Davis I" first="I. D." last="Davis">I. D. Davis</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Monash University and Eastern Health</s1>
<s2>Clayton, VIC</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Monash University and Eastern Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Bono, J S" sort="De Bono, J S" uniqKey="De Bono J" first="J. S." last="De Bono">J. S. De Bono</name>
<affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Royal Marsden Hospital and Institute of Cancer Research</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Evans, C P" sort="Evans, C P" uniqKey="Evans C" first="C. P." last="Evans">C. P. Evans</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>University of California</s1>
<s2>Davis</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of California</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Comprehensive Cancer Center</s1>
<s2>Sacramento</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Comprehensive Cancer Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fizazi, K" sort="Fizazi, K" uniqKey="Fizazi K" first="K." last="Fizazi">K. Fizazi</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institut Gustave Roussy, University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>University of Paris Sud</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Joshua, A M" sort="Joshua, A M" uniqKey="Joshua A" first="A. M." last="Joshua">A. M. Joshua</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Princess Margaret Cancer Centre</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Princess Margaret Cancer Centre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kim, C S" sort="Kim, C S" uniqKey="Kim C" first="C.-S." last="Kim">C.-S. Kim</name>
<affiliation wicri:level="3"><inist:fA14 i1="19"><s1>Asan Medical Center</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Corée du Sud</country>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kimura, G" sort="Kimura, G" uniqKey="Kimura G" first="G." last="Kimura">G. Kimura</name>
<affiliation wicri:level="3"><inist:fA14 i1="20"><s1>Nippon Medical School</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mainwaring, P" sort="Mainwaring, P" uniqKey="Mainwaring P" first="P." last="Mainwaring">P. Mainwaring</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Icon Cancer Care</s1>
<s2>South Brisbane</s2>
<s3>AUS</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Icon Cancer Care</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mansbach, H" sort="Mansbach, H" uniqKey="Mansbach H" first="H." last="Mansbach">H. Mansbach</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Medivation</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miller, K" sort="Miller, K" uniqKey="Miller K" first="K." last="Miller">K. Miller</name>
<affiliation wicri:level="3"><inist:fA14 i1="21"><s1>Charité-Universitätsmedizin Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Noonberg, S B" sort="Noonberg, S B" uniqKey="Noonberg S" first="S. B." last="Noonberg">S. B. Noonberg</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Medivation</s1>
<s2>San Francisco</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>19 aut.</sZ>
<sZ>21 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perabo, F" sort="Perabo, F" uniqKey="Perabo F" first="F." last="Perabo">F. Perabo</name>
<affiliation wicri:level="1"><inist:fA14 i1="22"><s1>Astellas Pharma Global Development</s1>
<s2>Northbrook, IL</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Astellas Pharma Global Development</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Phung, D" sort="Phung, D" uniqKey="Phung D" first="D." last="Phung">D. Phung</name>
<affiliation wicri:level="1"><inist:fA14 i1="22"><s1>Astellas Pharma Global Development</s1>
<s2>Northbrook, IL</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Astellas Pharma Global Development</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Saad, F" sort="Saad, F" uniqKey="Saad F" first="F." last="Saad">F. Saad</name>
<affiliation wicri:level="3"><inist:fA14 i1="17"><s1>Centre Hospitalier de l'Université de Montréal</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>24 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Scher, H I" sort="Scher, H I" uniqKey="Scher H" first="H. I." last="Scher">H. I. Scher</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>25 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Taplin, M E" sort="Taplin, M E" uniqKey="Taplin M" first="M.-E." last="Taplin">M.-E. Taplin</name>
<affiliation wicri:level="3"><inist:fA14 i1="23"><s1>Dana-Farber Cancer Institute</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>26 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><settlement type="city">Boston</settlement>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Venner, P M" sort="Venner, P M" uniqKey="Venner P" first="P. M." last="Venner">P. M. Venner</name>
<affiliation wicri:level="1"><inist:fA14 i1="18"><s1>Cross Cancer Institute and University of Alberta</s1>
<s2>Edmonton</s2>
<s3>CAN</s3>
<sZ>27 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Cross Cancer Institute and University of Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tombal, B" sort="Tombal, B" uniqKey="Tombal B" first="B." last="Tombal">B. Tombal</name>
<affiliation wicri:level="3"><inist:fA14 i1="24"><s1>Cliniques Universitaires Saint-Luc</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>28 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Medicine</term>
<term>Metastasis</term>
<term>Metastatic</term>
<term>Prostate cancer</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cancer de la prostate</term>
<term>Chimiothérapie</term>
<term>Métastase</term>
<term>Métastatique</term>
<term>Médecine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy. METHODS In this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalutamide (at a dose of 160 mg) or placebo once daily. The coprimary end points were radiographic progression-free survival and overall survival. RESULTS The study was stopped after a planned interim analysis, conducted when 540 deaths had been reported, showed a benefit of the active treatment. The rate of radiographic progression-free survival at 12 months was 65% among patients treated with enzalutamide, as compared with 14% among patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% confidence interval [CI], 0.15 to 0.23; P<0.001). A total of 626 patients (72%) in the enzalutamide group, as compared with 532 patients (63%) in the placebo group, were alive at the data-cutoff date (29% reduction in the risk of death; hazard ratio, 0.71; 95% CI, 0.60 to 0.84; P<0.001). The benefit of enzalutamide was shown with respect to all secondary end points, including the time until the initiation of cytotoxic chemotherapy (hazard ratio, 0.35), the time until the first skeletal-related event (hazard ratio, 0.72), a complete or partial soft-tissue response (59% vs. 5%), the time until prostate-specific antigen (PSA) progression (hazard ratio, 0.17), and a rate of decline of at least 50% in PSA (78% vs. 3%) (P<0.001 for all comparisons). Fatigue and hypertension were the most common clinically relevant adverse events associated with enzalutamide treatment. CONCLUSIONS Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>Canada</li>
<li>Corée du Sud</li>
<li>Espagne</li>
<li>France</li>
<li>Italie</li>
<li>Japon</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Berlin</li>
<li>Californie</li>
<li>Catalogne</li>
<li>Grand Londres</li>
<li>Hovedstaden</li>
<li>Latium</li>
<li>Massachusetts</li>
<li>Oregon</li>
<li>Québec</li>
<li>Région capitale de Séoul</li>
<li>Région de Bruxelles-Capitale</li>
<li>Région de Kantō</li>
<li>Washington (État)</li>
<li>État de New York</li>
</region>
<settlement><li>Barcelone</li>
<li>Berlin</li>
<li>Boston</li>
<li>Bruxelles</li>
<li>Copenhague</li>
<li>Londres</li>
<li>Montréal</li>
<li>Portland</li>
<li>Rome</li>
<li>San Francisco</li>
<li>Seattle</li>
<li>Séoul</li>
<li>Tokyo</li>
</settlement>
<orgName><li>Université de Washington</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Oregon"><name sortKey="Beer, T M" sort="Beer, T M" uniqKey="Beer T" first="T. M." last="Beer">T. M. Beer</name>
</region>
<name sortKey="Armstrong, A J" sort="Armstrong, A J" uniqKey="Armstrong A" first="A. J." last="Armstrong">A. J. Armstrong</name>
<name sortKey="Bhattacharya, S" sort="Bhattacharya, S" uniqKey="Bhattacharya S" first="S." last="Bhattacharya">S. Bhattacharya</name>
<name sortKey="Evans, C P" sort="Evans, C P" uniqKey="Evans C" first="C. P." last="Evans">C. P. Evans</name>
<name sortKey="Evans, C P" sort="Evans, C P" uniqKey="Evans C" first="C. P." last="Evans">C. P. Evans</name>
<name sortKey="Higano, C S" sort="Higano, C S" uniqKey="Higano C" first="C. S." last="Higano">C. S. Higano</name>
<name sortKey="Mansbach, H" sort="Mansbach, H" uniqKey="Mansbach H" first="H." last="Mansbach">H. Mansbach</name>
<name sortKey="Noonberg, S B" sort="Noonberg, S B" uniqKey="Noonberg S" first="S. B." last="Noonberg">S. B. Noonberg</name>
<name sortKey="Perabo, F" sort="Perabo, F" uniqKey="Perabo F" first="F." last="Perabo">F. Perabo</name>
<name sortKey="Phung, D" sort="Phung, D" uniqKey="Phung D" first="D." last="Phung">D. Phung</name>
<name sortKey="Rathkopf, D E" sort="Rathkopf, D E" uniqKey="Rathkopf D" first="D. E." last="Rathkopf">D. E. Rathkopf</name>
<name sortKey="Scher, H I" sort="Scher, H I" uniqKey="Scher H" first="H. I." last="Scher">H. I. Scher</name>
<name sortKey="Taplin, M E" sort="Taplin, M E" uniqKey="Taplin M" first="M.-E." last="Taplin">M.-E. Taplin</name>
</country>
<country name="France"><noRegion><name sortKey="Loriot, Y" sort="Loriot, Y" uniqKey="Loriot Y" first="Y." last="Loriot">Y. Loriot</name>
</noRegion>
<name sortKey="Fizazi, K" sort="Fizazi, K" uniqKey="Fizazi K" first="K." last="Fizazi">K. Fizazi</name>
</country>
<country name="Italie"><region name="Latium"><name sortKey="Sternberg, C N" sort="Sternberg, C N" uniqKey="Sternberg C" first="C. N." last="Sternberg">C. N. Sternberg</name>
</region>
</country>
<country name="Pays-Bas"><region name="Hovedstaden"><name sortKey="Iversen, P" sort="Iversen, P" uniqKey="Iversen P" first="P." last="Iversen">P. Iversen</name>
</region>
</country>
<country name="Espagne"><region name="Catalogne"><name sortKey="Carles, J" sort="Carles, J" uniqKey="Carles J" first="J." last="Carles">J. Carles</name>
</region>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Chowdhury, S" sort="Chowdhury, S" uniqKey="Chowdhury S" first="S." last="Chowdhury">S. Chowdhury</name>
</noRegion>
<name sortKey="De Bono, J S" sort="De Bono, J S" uniqKey="De Bono J" first="J. S." last="De Bono">J. S. De Bono</name>
</country>
<country name="Australie"><noRegion><name sortKey="Davis, I D" sort="Davis, I D" uniqKey="Davis I" first="I. D." last="Davis">I. D. Davis</name>
</noRegion>
<name sortKey="Mainwaring, P" sort="Mainwaring, P" uniqKey="Mainwaring P" first="P." last="Mainwaring">P. Mainwaring</name>
</country>
<country name="Canada"><noRegion><name sortKey="Joshua, A M" sort="Joshua, A M" uniqKey="Joshua A" first="A. M." last="Joshua">A. M. Joshua</name>
</noRegion>
<name sortKey="Saad, F" sort="Saad, F" uniqKey="Saad F" first="F." last="Saad">F. Saad</name>
<name sortKey="Venner, P M" sort="Venner, P M" uniqKey="Venner P" first="P. M." last="Venner">P. M. Venner</name>
</country>
<country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Kim, C S" sort="Kim, C S" uniqKey="Kim C" first="C.-S." last="Kim">C.-S. Kim</name>
</region>
</country>
<country name="Japon"><region name="Région de Kantō"><name sortKey="Kimura, G" sort="Kimura, G" uniqKey="Kimura G" first="G." last="Kimura">G. Kimura</name>
</region>
</country>
<country name="Allemagne"><region name="Berlin"><name sortKey="Miller, K" sort="Miller, K" uniqKey="Miller K" first="K." last="Miller">K. Miller</name>
</region>
</country>
<country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Tombal, B" sort="Tombal, B" uniqKey="Tombal B" first="B." last="Tombal">B. Tombal</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004184 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004184 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:14-0207191
   |texte=   Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri